TTD | Drug: D0Z8PX

Drug General Information
Drug ID	D0Z8PX
Former ID	DNC011052
Drug Name	LARGAZOLE
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[530933]
Formula	C29H42N4O5S3
Canonical SMILES	CCCCCCCC(=O)SCCC=CC1CC(=O)NCC2=NC(=CS2)C3=NC(CS3)(C(=O)<br />NC(C(=O)O1)C(C)C)C
InChI	1S/C29H42N4O5S3/c1-5-6-7-8-9-13-24(35)39-14-11-10-12-20-15-22(34)30-16-23-31-21(17-40-23)26-33-29(4,18-41-26)28(37)32-25(19(2)3)27(36)38-20/h10,12,17,19-20,25H,5-9,11,13-16,18H2,1-4H3,(H,30,34)(H,32,37)/b12-10+/t20-,25-,29+/m1/s1
InChIKey	AXESYCSCGBQJBL-BNQQNEQWSA-N
PubChem Compound ID	24757913
Target and Pathway
Target(s)	Histone deacetylase 1	Target Info	Inhibitor	[530933]
Target(s)	Histone deacetylase 4	Target Info	Inhibitor	[530933]
KEGG Pathway	Cell cycle
	Notch signaling pathway
	Thyroid hormone signaling pathway
	Huntington's disease
	Amphetamine addiction
	Alcoholism
	Epstein-Barr virus infection
	Pathways in cancer
	Transcriptional misregulation in cancer
	Viral carcinogenesis
	MicroRNAs in cancer
	Chronic myeloid leukemiahsa05034:Alcoholism
NetPath Pathway	TCR Signaling PathwayNetPath_14:IL2 Signaling Pathway
PANTHER Pathway	Wnt signaling pathway
PANTHER Pathway	p53 pathway
Pathway Interaction Database	Regulation of nuclear SMAD2/3 signaling
	Notch signaling pathway
	E2F transcription factor network
	Presenilin action in Notch and Wnt signaling
	Signaling events mediated by HDAC Class I
	Regulation of Telomerase
	Glucocorticoid receptor regulatory network
	Sumoylation by RanBP2 regulates transcriptional repression
	Regulation of Androgen receptor activity
	IL3-mediated signaling events
	Validated nuclear estrogen receptor alpha network
	Retinoic acid receptors-mediated signaling
	Hedgehog signaling events mediated by Gli proteins
	Regulation of nuclear beta catenin signaling and target gene transcription
	Validated targets of C-MYC transcriptional repression
	Regulation of retinoblastoma protein
	Notch-mediated HES/HEY networkhdac_classii_pathway:Signaling events mediated by HDAC Class II
	Signaling events mediated by HDAC Class III
Reactome	G0 and Early G1
	p75NTR negatively regulates cell cycle via SC1
	Formation of the beta-catenin:TCF transactivating complex
	NOTCH1 Intracellular Domain Regulates Transcription
	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
	Constitutive Signaling by NOTCH1 PEST Domain Mutants
	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
	HDACs deacetylate histones
	Deactivation of the beta-catenin transactivating complex
	NoRC negatively regulates rRNA expression
	RNA Polymerase I Transcription Initiation
	Factors involved in megakaryocyte development and platelet productionR-HSA-2122947:NOTCH1 Intracellular Domain Regulates Transcription
WikiPathways	SIDS Susceptibility Pathways
	Notch Signaling Pathway
	TGF beta Signaling Pathway
	IL-6 signaling pathway
	Apoptosis-related network due to altered Notch3 in ovarian cancer
	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
	Notch Signaling Pathway
	Retinoblastoma (RB) in Cancer
	Neural Crest Differentiation
	TWEAK Signaling Pathway
	Integrated Breast Cancer Pathway
	Signalling by NGF
	RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
	Mitotic G1-G1/S phases
	Factors involved in megakaryocyte development and platelet production
	Cell Cycle
	Androgen receptor signaling pathwayWP474:Endochondral Ossification
	Cardiac Hypertrophic Response
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
	TarBasePathway
	MicroRNAs in cardiomyocyte hypertrophy
References
Ref 530933	J Med Chem. 2010 Jun 24;53(12):4654-67.Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
Ref 530933	J Med Chem. 2010 Jun 24;53(12):4654-67.Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.

Drug Information